96 results about "Genetic vaccination" patented technology

A method is disclosed for enhanced vaccination and genetic vaccination of mammals. The vaccination is accomplished by delivering molecules such as proteins and nucleic acids into skeletal muscle and other cells residing in the skeletal muscle in vivo. The protein or nucleic acid is first injected into the muscle at one or multiple sites. Immediately or shortly after injection, electrodes are placed flanking the injection site and a specific amount of electrical current is passed through the muscle. The electrical current makes the muscle permeable, thus allowing the pharmaceutical drug or nucleic acid to enter the cell. The efficiency of transfer permits robust immune responses using DNA vaccines and produces sufficient secreted proteins for systemic biological activity to be observed.

A drug delivery system comprising pH triggerable particles is described. The pH triggerable particles comprise and agent(s) to be delivered, which is encapsulated in a matrix comprising a pH trigger agent and a polymer. Agents including nucleic acids may be delivered intracellularly using the inventive pH triggerable particles. Upon exposure to an acidic environment such as the endosome or phagosome of a cell, the particles dissolve or disrupt due to protonation or an increase in solubility of the pH triggering agent. Pharmaceutical compositions and methods of preparing and administering these particles are also described. These particles may be particularly useful in genetic vaccination.

The invention relates to an RNA comprising at least one open reading frame (ORF) and comprising at least one modification, which increases the expression of the encoded peptide or protein. Furthermore, the invention relates to the medical use of such a modified RNA administered to a subject by jet injection. The invention relates further to a pharmaceutical composition and to a kit of parts comprising said modified RNA for administration by jet injection, preferably for use in the field of gene therapy and/or genetic vaccination. Additionally, the invention relates to a method for enhancing the (localized) expression of RNA-encoded peptides or proteins in the dermis or muscle (of a mammal) comprising administering the modified RNA by jet injection. And finally, the invention relates to a method of treatment comprising administering the modified RNA by jet injection to a subject in need thereof.

There is disclosed a genetic vaccination device and a process for forming an injection solution therefor, the device comprising a syringe and canula coupled to a membrane adsorber having genetic material adsorbed thereon, and the process comprising eluting the genetic material from the membrane adsorber so as to form an injection solution containing the genetic material.

The invention pertains to biological genetic engineering field, specificly relating to SARS vaccine of adenovirus carrier and preparation method, application of related coronavirus S gene in preparation of the SARS vaccine for preventing SARS. Through a bioengineering means, the related coronary virus S gene and a defective adenovirus are recombined, which makes protective immunogen protein or polypeptide expressing in it. A genic vaccine that can arouse the mucosal immunogenicity is produced through amplifying training, purification, and preparation, which induces a immunity reaction in the respiratory mucosa, makes the organism produce the corresponding antibody, and prevents virus from infection. Compared with the traditional inactivated viral particles vaccine, the invention has a high safety; it is convenient to operate; it is not limited by the specific conditions such as intramuscular injection; and it has an extensive clinical application prospect.

The invention generally concerns compositions and methods for genetic vaccination with amyloid beta (Aβ) protein. Such vaccines may provide effective treatment for neurodegenerative disease such as Alzheimer's disease. Vaccination methods are can be used to induce a Th2 type immune response directed to Aβ. This immune response id shown to substantially reduce Aβ concentration and Aβ plaque size in an Alzheimer's model system.

The invention concerns the field of genetic vaccination, in particular RNA vaccines. The present invention provides an mRNA for use in the treatment and/or prevention of a disease, wherein the mRNA is administered to the epidermis. Furthermore, the invention provides compositions comprising the mRNA for epidermal administration or kits comprising the mRNA for epidermal administration. Moreover, the invention concerns the medical use of the mRNA or compositions comprising the mRNA, wherein the mRNA or compositions comprising the mRNA are administered to the epidermis.

The invention discloses a tuberculosis gene vaccine based on T cell epitopes, wherein a full-length gene, embedded with four T cell epitope polypeptide genes which come from mycobacterium tuberculosis antigen, of mycobacterium tuberculosis heat shock protein is inserted into a vector. The invention also discloses a method for preparing the vaccine, which comprises the following steps: four T cell epitope genes, namely EAST-6189-228, Ag85A369-405, CFP10162-207 and Ag85B420-459 which come from the mycobacterium tuberculosis antigen are inserted into an HSP65 full-length gene. The invention also discloses application of an ECANS tuberculosis gene vaccine. Through the intramuscular injection of the gene vaccine into an immune mouse, the experiment proves that the vaccine can induce a specific antibody which aims at a plurality of tuberculosis antigens to response, can induce stronger tuberculosis specific killing response, can induce Th1 immune response at the same time, secrete high-level IFN gamma, and is a good vaccine for preventing and treating tuberculosis.

An objective of the present invention is to provide a safe and effective vaccine therapy for Alzheimer's disease. A minus strand RNA viral vector carrying amyloid gene was constructed, and administered intranasally to 24- to 25-months-old APP transgenic mice. The level of serum anti-A 42 antibody was determined and showed to be markedly higher than the control. The results of histological investigation showed that the administration of a vector of the present invention markedly reduced senile plaques in all of the frontal lobe, parietal lobe, and hippocampus. The brain A level was also markedly reduced. Furthermore, the administration of a vector of the present invention did not result in lymphocyte infiltration in the central nervous system.

The invention relates to the technical field of gene engineering, in particular to an immune enhanced gene vaccine of a hepatitis B virus core antigen (HBcAg). The vaccine is an immune stimulating complex (ISCOM) vaccine consisting of HBcAg and OX40 ligand (OX40L) dual-gene co-expression recombinant eukaryotic vector, saponin Quil A, cholesterol and lecithin. The vaccine can promote immune response of specific T cells of the HBcAg and efficiently induce the anti-virus replication capacity of immune cells, and has good application prospect in the field of hepatitis B virus infection resistance. The invention also relates to a preparation method for the vaccine with simple and convenient operation and low cost.

The invention aims at providing a duck plague virus gene deletion transfer vector and an application of the duck plague virus gene deletion transfer vector. The transfer vector is subjected to homologous recombination with duck plague virus to obtain duck plague virus gene deletion engineering strains which can be prepared into a high-safety and high-prevention-effect duck plague virus gene deletion vaccine. The duck plague virus gene deletion vaccine does not influence the virus immunogenicity while lowering down the virus pathogenicity; therefore, the prepared duck plague virus gene deletion vaccines are high in safety, able to remain the original virus immunogenicity, suitable for prevention and control for the current duck plague diseases in domestic, and beneficial for the cleaning treatment of duck plague in a duck farm; in addition, the recombined duck plague virus strains do not contain any exogenous genes; and compared with the similar duck plague virus gene vaccines reported in the prior art, the duck plague virus gene deletion vaccine has the advantage that no EGFP (Enhanced Green Fluorescent Protein), lacZ and other marker gene are contained, so that the bio-safety is improved.

The invention discloses a method for preparing an actinobacillus pleuropneumoniae (App) bacterial ghost and a method for preparing a subunit vaccine by loading a pasteurella antigen with the App bacterial ghost. A recombinant swine App bacterial ghost is prepared by controllable double-cracking technology and a pasteurella protection gene is introduced into an App bacterial ghost carrier, so that swine pleuropneumonia and a pasteurella bigeminal gene vaccine for preventing and treating swine pasteurellosis and swine pleuropneumonia are obtained. The preparation of the bacterial ghost carrier and the application of the bacterial ghost carrier to the prevention and treatment of important animal epidemic diseases are realized and a method is provided for the research of a multi-geminal gene vaccine at the same time. An animal experiment indicates that the protection rates of the bigeminal vaccine on infectious swine pleuropneumonia and pasteurellosis are up to 99 percent and 99.2 percent respectively.

The present invention discloses a gene vaccine for resisting SARS coronavirus and its application, including eucaryotic expressino plasmid containing total or partial gene fragment of total-length gene sequence of SARS coronavirus S protein. The nucleotide sequence of coded SARS coronavirus S protein can be operatively connected with a promotor, then it can express the complete or partial polypeptide of the coded SARS coronavirus S protein in vivo. The described gene vaccine can be used for immunizing host including human body and rodent, for example mouse to make it produce specific protective body fluid immune and cell immune to resist the infection of SARS coronavirus. Said invention is good in stability, convenient in production and low in cost.

The invention discloses a fusion protein gene which is formed by sequentially connecting an antigen gene Rv3615c, an antigen gene Mtb10.4 and an antigen gene Rv2660c in series from a 5' end to a 3' end. The invention also provides a three-antigen fusion gene vaccine of mycobacterium tuberculosis as well as a preparation method and application of the three-antigen fusion gene vaccine of the mycobacterium tuberculosis, wherein the three-antigen fusion gene vaccine is composed of a carrier, and a segment of the fusion protein gene is inserted to the carrier. Rat immunological experiments show that the three-antigen fusion gene vaccine of the mycobacterium tuberculosis can be used for inducing a better cellular immunological response. The three-antigen fusion gene vaccine of the mycobacterium tuberculosis, disclosed by the invention, can be used for inducing a specific killing response and a stronger CD4<+> and CD8<+>T cellular immune protection reaction having an important protection effect on mycobacterium tuberculosis infection, can be used for effectively resisting the mycobacterium tuberculosis infection, and plays a better protection effect on tuberculosis infected rats.

The invention discloses a mucosa M-cell targeted viral myocarditis gene vaccine. The vaccine is prepared by compounding a mucosa delivery system capable of targeting mucosa M-cells and B3-type coxsackie virus antigen encoding plasmids through cross-linking copolymerization. The invention further discloses a preparation method of the gene vaccine. The invention further discloses a preparation method of the mucosa delivery system capable of targeting the mucosa M-cells, and the mucosa delivery system is acquired after stable amide-ester bonds are formed by carboxyl groups and amino groups in deacetylated chitosan, wherein the carboxyl groups in peptide fragment CPE30 are targeted by M-cells which are activated by using EDC (Dichloroethane) and NHS (N-Hydroxysuccinimide). By nasally dropping the gene vaccine onto immunized mice, the gene vaccine is proved to be capable of effectively inducing the response between specific antigen serum and mucoantibody, obviously enhancing the local specific T-cell killing ability of the whole body and gastrointestinal mucosa and significantly improving the ability of mice for resisting B3-type coxsackie virus, thereby being an excellent prophylactic vaccine for viral myocarditis.

The invention describes new peptides containing epitopes recognized by CD4+ natural killer T (NKT) cells for increasing activity for use in infectious diseases, autoimmune diseases, immune reaction to administration of allofactors, allergic diseases, therapy of tumors, prevention of graft rejection and prevention of immunization against viral proteins used in gene therapy or gene vaccination.

The invention discloses a gene vaccine vector, and a preparation method and an application thereof; the gene vaccine vector is a supramolecular hydrogel formed through phosphatase catalysis of a small-molecular peptide; the small-molecular peptide has the structural formula represented by the formula (I), wherein when m=1, n=0, 1, 2 or 3; when n=1, m=1, 2 or 3. The gene vaccine vector after being loaded with DNA has the advantages of strong immunogenicity, large load capacity, no obvious toxicity and injectable immunity. The gene vaccine vector is mild in preparation conditions and simple in process.

The present invention discloses a viral myocarditis gene vaccine, Said vaccine is constructed by using B3 type Coxsackie virus structural protein VPI gene and pcDNA carrier together, and its exterior is covered with a biological polysaccharide. It also discloses a method for preparing said gene vaccine and the application of said gene vaccine in preparation of medicine for preventing viral myocarditis.

The invention discloses a eucaryon expression vector of a DNA vaccine and the application. The eucaryon expression vector of DNA vaccine is a recombination pVAX1 eucaryon expression vector which is got by adding the internal ribosome in pVAX1 vector skeleton and entering the site coded sequence. The eucaryon expression vector may show the wide spectrum curing function for breast cancer, pancreatic cancer, restocarcinoma and multi-type malignancy solid tumor, which has good humoral immunity and cell-mediated immunity effect, and inhibits the growth of the tumor.

Genetic vaccine which comprises plasmid(s) containing genes coding for antigens of enterotoxigenic Escherichia coli (ETEC) strains is disclosed. Additionally, plasmids may consist of multiple copies of the same antigen (i.e. K88 or K99 fimbrial antigen) or multiple antigens (ie. K88 and K99 fimbrial antigens) and genetic adjuvants such as cytokines (IL-2, IL-4 & GM-CSF), costimulatory molecules (CD80 & CD86) or chemokines or immunostimulatory sequences. A method for isolating antibodies from chicken egg yolk for passive immunization of animals, as well as humans to control diarrhoeal diseases using the genetic vaccines is also disclosed.